Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.68 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.50 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.50 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9622956 | 0.98 | BCL9 (0.66) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL531007 | 0.94 | BCL9 (0.76) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL531155 | 0.92 | BCL9 (0.73) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL7079988 | 0.92 | BCL9 (0.73) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL530771 | 0.92 | BCL9 (0.73) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL570540 | 0.92 | BCL9 (0.73) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL3919600 | 0.90 | BCL9 (0.76) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL9657255 | 0.88 | BCL9 (0.68) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL957930 | 0.87 | BCL9 (0.81) | BCL9CTNNB1TDP1MAPTKMT2A | |
| SCHEMBL1400174 | 0.86 | BCL9 (0.80) | BCL9CTNNB1TDP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093696-B2 | Nitric oxide donating carnosine compounds | NICOX SCIENCE IRELAND (IE) | 2018-10-09 | — | — | US | disclosed |
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SA (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SA (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SA (FR) | 2017-10-12 | — | — | US | disclosed |
| EP-2993172-B1 | Nitric oxide donating carnosine compounds | NICOX SCIENCE IRELAND (IE) | 2017-04-19 | — | — | EP | disclosed |
| EP-2993172-B1 | Nitric oxide donating carnosine compounds | NICOX SCIENCE IRELAND (IE) | 2017-04-19 | — | — | EP | disclosed |
| WO-2016034619-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034619-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-03-10 | — | — | WO | disclosed |
| EP-2993172-A1 | Nitric oxide donating carnosine compounds | Nicox Science Ireland (IE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2993172-A1 | Nitric oxide donating carnosine compounds | Nicox Science Ireland (IE) | 2016-03-09 | — | — | EP | disclosed |
| WO-2008113863-A2 | NITROSATED DERIVATIVES OF 2,5-DIHYDROXYBENZENE COMPOUNDS | ACTION MEDICINES, S.L. (ES) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113863-A2 | NITROSATED DERIVATIVES OF 2,5-DIHYDROXYBENZENE COMPOUNDS | ACTION MEDICINES, S.L. (ES) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291920-A1 | NITRIC OXIDE DONATING CARNOSINE COMPOUNDS | NOS1, NOS2, NOS3 | BCL9 2506/4885CTNNB1 4828/4885TDP1 343/4885 |
| US-10093696-B2 | Nitric oxide donating carnosine compounds | NOS1, NOS2, NOS3 | BCL9 2506/4885CTNNB1 4828/4885TDP1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.